Unlocking The Potential of The KLHL22 Gene (G84861)

Target Name: KLHL22

NCBI ID: G84861

KLHL22

Unlocking The Potential of The KLHL22 Gene

The KLHL22 gene is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and expression pattern make it an attractive target for researchers to study and develop new treatments.

The KLHL22 gene was first identified in 2012 using next-generation sequencing techniques. It is located on chromosome 6p21.2 and has a length of 11.6 kb. The gene encodes a protein that is expressed in many different tissues and cells in the body.

One of the most significant features of the KLHL22 gene is its ability to self-cleave. This self-cleavage mechanism allows the protein to be cleaved by various proteases, including those involved in the immune response and cell signaling pathways. This cleavage generates a unique post-translational modification (PTM) that has been identified as KLHL22-N-terminal 伪-helix.

KLHL22-N-terminal 伪-helix is 鈥嬧?媋 protein structure ubiquitous in various organisms. This structure plays an important role in cell signaling and immune responses. In addition, this structure is closely related to the occurrence and development of diseases and is therefore considered a potential drug target.

In cancer, abnormal expression of KLHL22 gene is one of the important factors leading to tumor occurrence and progression. Many studies have shown that the expression level of KLHL22 gene is closely related to the prognosis and treatment response of various cancers. In addition, the expression level of KLHL22 gene is also closely related to the invasion and metastasis of tumors. Therefore, the KLHL22 gene is considered an important target for cancer treatment.

In neurodegenerative diseases, the KLHL22 gene is also considered a potential drug target. Neurodegenerative diseases include diseases such as Alzheimer's disease, Parkinson's disease and multiple sclerosis. These diseases cause nerve cell death and damage, leading to cognitive and motor impairments.

The KLHL22 gene is closely related to the occurrence and development of these diseases. For example, studies have found that expression levels of the KLHL22 gene are associated with cognitive decline and neuronal death in patients with Alzheimer's disease. In addition, the KLHL22 gene is also closely related to the onset and development of diseases such as Parkinson's disease and multiple sclerosis. Therefore, the KLHL22 gene is considered an important target for the treatment of these diseases.

In the immune system, the KLHL22 gene is also considered a potential drug target. The protein encoded by the KLHL22 gene can regulate the functions of immune cells, including T cell activation, proliferation, and sorting. In addition, the KLHL22 gene is also closely related to the tumorigenesis and progression of immune cells. Therefore, the KLHL22 gene is considered an important target for immune system therapy.

In addition to being a drug target, the KLHL22 gene is also considered a potential biomarker. Since the KLHL22 gene is ubiquitous in a variety of organisms, it can be used as a biomarker to detect early expression levels of disease. In addition, the expression level of KLHL22 gene is also closely related to the development and severity of the disease, so it can be used as a biomarker to evaluate the prognosis of the disease.

The potential role of the KLHL22 gene as a drug target, biomarker, and disease treatment has aroused widespread research interest. As technology continues to advance, researchers will continue to explore the role of the KLHL22 gene in drug research and treatment, and reveal its importance in the biomedical field.

Protein Name: Kelch Like Family Member 22

Functions: Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin ligase complex required for chromosome alignment and localization of PLK1 at kinetochores. The BCR(KLHL22) ubiquitin ligase complex mediates monoubiquitination of PLK1, leading to PLK1 dissociation from phosphoreceptor proteins and subsequent removal from kinetochores, allowing silencing of the spindle assembly checkpoint (SAC) and chromosome segregation. Monoubiquitination of PLK1 does not lead to PLK1 degradation (PubMed:19995937, PubMed:23455478). The BCR(KLHL22) ubiquitin ligase complex is also responsible for the amino acid-stimulated 'Lys-48' polyubiquitination and proteasomal degradation of DEPDC5. Through the degradation of DEPDC5, releases the GATOR1 complex-mediated inhibition of the TORC1 pathway. It is therefore an amino acid-dependent activator within the amino acid-sensing branch of the TORC1 pathway, indirectly regulating different cellular processes including cell growth and autophagy (PubMed:29769719)

The "KLHL22 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KLHL22 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets